MANNHEIM, Germany (AP) — MANNHEIM, Germany (AP) — Affimed N.V. (AFMD) on Thursday reported a loss of $16.6 million in its third quarter.
On a per-share basis, the Mannheim, Germany-based company said it had a loss of $1.03.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.14 per share.
The drug developer posted revenue of $170,400 in the period. Its adjusted revenue was $170,000.
The company's shares closed at $3.75. A year ago, they were trading at $3.28.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AFMD at https://www.zacks.com/ap/AFMD
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。